Literature DB >> 1809047

Reversal of central benzodiazepine effects by intravenous flumazenil.

M S Clark1, J E Lindenmuth, B W Jafek, G E Fryer, J R Goldberg.   

Abstract

The purpose of this study was to determine the efficacy of flumazenil in safely expediting patient recovery from benzodiazepine sedation. This double-blind, randomized, placebo-controlled study involved 30 patients who received conscious sedation induced by intravenous midazolam given for a dental surgical procedure. Patients who received flumazenil were rated significantly more alert than were placebo-treated patients at 5 and 15 min following test drug administration. They also had significantly superior scores on the digital symbol substitution test and on tests in a comprehensive modified neurological examination 5 min after receiving flumazenil. Group differences were not as impressive on recall and recognition tests. However, flumazenil patients scored somewhat more favorably than the placebo group patients in identifying simple objects they had been shown during the observation period following surgery. Flumazenil appears to be a promising drug for reversing midazolam conscious sedation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1809047      PMCID: PMC2162358     

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  5 in total

1.  Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans.

Authors:  U Klotz; G Ziegler; L Ludwig; I W Reimann
Journal:  J Clin Pharmacol       Date:  1985-09       Impact factor: 3.126

2.  Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.

Authors:  U Klotz; G Ziegler; I W Reimann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Midazolam, diazepam, and placebo as intravenous sedatives for dental surgery.

Authors:  M S Clark; L M Silverstone; J M Coke; J Hicks
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1987-01

4.  First clinical investigation of the benzodiazepine antagonist Ro 15-1788 in comatose patients.

Authors:  G Scollo-Lavizzari
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

5.  Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788.

Authors:  U Klotz; T Duka; R Dorow; A Doenicke
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

  5 in total
  1 in total

1.  Summary of the scientific literature for pain and anxiety control in dentistry.

Authors:  L C Hassett
Journal:  Anesth Prog       Date:  1992
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.